Sabinsa received the coveted 2009 Thomas Alva Edison Patent Award in the Nutraceuticals Category for the patent on its proprietary product, GarCitrin®. The patent, US 7063861, is entitled “Bioavailable Composition of Natural and Synthetic HCA.”
The Thomas Alva Edison Patent Awards were presented by the Research and Development Council of New Jersey at the Council’s annual fall dinner, held at the Liberty Science Center on November 5th. For nearly 20 years a small group of researchers, engineers, inventors and industry professionals have worked to create a higher-level of public awareness of the many outstanding New Jersey inventors that have impacted society.
“We are honored to receive the 2009 Thomas Alva Edison Patent Award,” said Sabinsa founder Dr. Muhammed Majeed. “We have long held the belief that science and innovation can benefit human nutrition, and it is gratifying to have that commitment validated by this distinguished organization.” |